H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Biology and Biochemistry D-index 48 Citations 7,823 113 World Ranking 11314 National Ranking 327

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cancer
  • Enzyme

His scientific interests lie mostly in Cell biology, Cancer research, Cell cycle, Cyclin B and Histone deacetylase. His research integrates issues of Cell cycle checkpoint, Biochemistry and Centrosome in his study of Cell biology. Brian Gabrielli has included themes like Pathological, Downregulation and upregulation, Immunology, Frameshift mutation and Blot in his Cancer research study.

Brian Gabrielli interconnects Carcinogenesis, microRNA and Computational biology in the investigation of issues within Cell cycle. Brian Gabrielli combines subjects such as Cyclin A and G1/S transition with his study of Cyclin B. His work carried out in the field of Histone deacetylase brings together such families of science as Sodium butyrate, Acetylation, Kinase and Cytotoxicity.

His most cited work include:

  • ATM associates with and phosphorylates p53: mapping the region of interaction (438 citations)
  • The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition (239 citations)
  • Histone Deacetylase Inhibitors Trigger a G2 Checkpoint in Normal Cells That Is Defective in Tumor Cells (232 citations)

What are the main themes of his work throughout his whole career to date?

Brian Gabrielli mainly investigates Cancer research, Cell biology, Melanoma, Cell cycle and Mitosis. The concepts of his Cancer research study are interwoven with issues in Cancer, Immunology, Histone deacetylase, Histone and In vivo. His research in Cell biology intersects with topics in Cyclin-dependent kinase 1, Biochemistry, Cyclin B, Molecular biology and Mitotic exit.

His Melanoma research incorporates themes from Cell, Cell cycle phase and CDKN2A. His research investigates the connection between Cell cycle and topics such as Cytotoxic T cell that intersect with issues in Cell culture. His work deals with themes such as Alisertib, Cytoplasm and Aurora B kinase, which intersect with Mitosis.

He most often published in these fields:

  • Cancer research (45.65%)
  • Cell biology (41.30%)
  • Melanoma (25.54%)

What were the highlights of his more recent work (between 2016-2021)?

  • Cancer research (45.65%)
  • Melanoma (25.54%)
  • Cell biology (41.30%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Cancer research, Melanoma, Cell biology, In vivo and Mitosis. His study in Cancer research is interdisciplinary in nature, drawing from both Cancer, Aurora kinase, Cell cycle checkpoint, Immune system and Alisertib. His Cell cycle checkpoint research is included under the broader classification of Cell cycle.

His Melanoma study combines topics from a wide range of disciplines, such as Cancer cell, Viability assay, Cell and DNA repair. His study in Cell biology is interdisciplinary in nature, drawing from both Microphthalmia-associated transcription factor and Melanocyte. His research in the fields of Mitotic inhibitor overlaps with other disciplines such as Vinblastine.

Between 2016 and 2021, his most popular works were:

  • CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer (33 citations)
  • Distinct histone modifications denote early stress-induced drug tolerance in cancer. (26 citations)
  • Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints. (20 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • Enzyme

Brian Gabrielli mainly investigates Cancer research, Mitosis, Cancer, Melanoma and Cell biology. His Cancer research study integrates concerns from other disciplines, such as Cell cycle, Aurora kinase, Aurora inhibitor, Alisertib and Cytotoxicity. Brian Gabrielli works mostly in the field of Cell cycle, limiting it down to topics relating to Function and, in certain cases, Cell cycle checkpoint.

His work deals with themes such as Cyclin-dependent kinase 1, Genome instability, Cyclin B, Breast cancer and In vivo, which intersect with Mitosis. His Melanoma research incorporates themes from Immunostaining, Pharmacology and MAPK/ERK pathway. His Cell biology research is multidisciplinary, incorporating elements of Mitotic catastrophe and LNCaP.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

ATM associates with and phosphorylates p53: mapping the region of interaction

Kum Kum Khanna.;Katherine E. Keating;Sergei Kozlov;Shaun Scott.
Nature Genetics (1998)

617 Citations

Histone Deacetylase Inhibitors Trigger a G2 Checkpoint in Normal Cells That Is Defective in Tumor Cells

Ling Qiu;Andrew Burgess;David P. Fairlie;Helen Leonard.
Molecular Biology of the Cell (2000)

331 Citations

The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition

Nicole Cloonan;Mellissa K Brown;Anita L Steptoe;Shivangi Wani.
Genome Biology (2008)

301 Citations

Cdk1/Erk2- and Plk1-dependent phosphorylation of a centrosome protein, Cep55, is required for its recruitment to midbody and cytokinesis

Megan Fabbro;Bin-Bing Zhou;Mikiko Takahashi;Boris Sarcevic.
Developmental Cell (2005)

293 Citations

Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells

B. G. Gabrielli;C. P. C. De Souza;I. D. Tonks;J. M. Clark.
Journal of Cell Science (1996)

277 Citations

Histone-Deacetylase Inhibitors for the Treatment of Cancer

Ralph K. Lindemann;Brian G. Gabrielli;Ricky W. Johnstone.
Cell Cycle (2004)

200 Citations

Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity.

Andrew J. Burgess;Sandra Pavey;Robyn Warrener;Lisa-Jane K. Hunter.
Molecular Pharmacology (2001)

185 Citations

APC mutation and tumour budding in colorectal cancer

J R Jass;M Barker;L Fraser;M D Walsh.
Journal of Clinical Pathology (2003)

179 Citations

Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints

Robyn Warrener;Heather Beamish;Andrew Burgess;Nigel J. Waterhouse.
The FASEB Journal (2003)

178 Citations

Centrosomal and cytoplasmic Cdc2/cyclin B1 activation precedes nuclear mitotic events.

C. P. C. De Souza;K. A. O. Ellem;B. G. Gabrielli.
Experimental Cell Research (2000)

175 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Brian Gabrielli

Kum Kum Khanna

Kum Kum Khanna

QIMR Berghofer Medical Research Institute

Publications: 51

Martin F. Lavin

Martin F. Lavin

University of Queensland

Publications: 50

Helen Piwnica-Worms

Helen Piwnica-Worms

Washington University in St. Louis

Publications: 36

Nicholas K. Hayward

Nicholas K. Hayward

QIMR Berghofer Medical Research Institute

Publications: 35

Bernard Ducommun

Bernard Ducommun

Federal University of Toulouse Midi-Pyrénées

Publications: 35

Nikolas K. Haass

Nikolas K. Haass

University of Queensland

Publications: 30

Ricky W. Johnstone

Ricky W. Johnstone

Peter MacCallum Cancer Centre

Publications: 29

Alessandro Lugli

Alessandro Lugli

University of Bern

Publications: 23

Inti Zlobec

Inti Zlobec

University of Bern

Publications: 23

Michael B. Yaffe

Michael B. Yaffe

MIT

Publications: 22

Steven Grant

Steven Grant

Virginia Commonwealth University

Publications: 20

James L. Maller

James L. Maller

University of Colorado Denver

Publications: 19

Richard A. Sturm

Richard A. Sturm

University of Queensland

Publications: 19

Grant A. McArthur

Grant A. McArthur

Peter MacCallum Cancer Centre

Publications: 18

David L. Duffy

David L. Duffy

QIMR Berghofer Medical Research Institute

Publications: 16

Matthew J. Simpson

Matthew J. Simpson

Queensland University of Technology

Publications: 15

Something went wrong. Please try again later.